Gainers
-
Bioverativ Inc (NASDAQ: BIVV) climbed 62.1
percent to $103.95. Sanofi SA (ADR) (NYSE: SNY)
announced plans to acquire Bioverativ for $11.6 billion, or $105 per share in cash.
-
Validus Holdings, Ltd. (NYSE: VR) shares jumped 44.4
percent to $67.48 after American International Group Inc (NYSE: AIG) announced plans to acquire Validus for $68 per share in cash.
-
Juno Therapeutics Inc (NASDAQ: JUNO) gained 26.9
percent to $86.03 as the company agreed to be acquired for $87 per share in cash by Celgene Corporation (NASDAQ:
CELG).
-
Sorrento Therapeutics Inc (NASDAQ: SRNE) shares
rose 19.5 percent to $7.65.
-
ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) gained 16.6
percent to $4.99.
-
Barnwell Industries, Inc. (NYSE: BRN) shares rose
16.5 percent to $2.79.
-
Array Biopharma Inc (NASDAQ: ARRY) shares gained
15.3 percent to $15.15. Array BioPharma disclosed that combination of encorafenib, binimetinib and cetuximab demonstrated an 8
month median progression-free survival in BRAF-mutant colorectal cancer in updated safety lead-in results from BEACON Phase 3
trial.
-
FirstEnergy Corp. (NYSE: FE) shares rose 13.3 percent
to $33.30 after announcing $2.5 billion in financing from hedge funds including Elliott Management.
-
Beyondspring Inc (NASDAQ: BYSI) shares gained
12.7 percent to $29.30.
-
Aspen Insurance Holdings Limited (NYSE: AHL) shares
rose 11.3 percent to $42.75.
-
Intrexon Corp (NYSE: XON) surged 11.2 percent to
$14.45 after dropping 4.62 percent on Friday.
-
Sangamo Therapeutics Inc (NASDAQ: SGMO) shares
jumped 10.1 percent to $19.55 after gaining 1.43 percent on Friday.
-
bluebird bio Inc (NASDAQ: BLUE) shares gained 9.4
percent to $192.40 after dropping 3.38 percent on Friday.
-
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)
shares rose 9 percent to $53.60. Evercore ISI Group upgraded Ultragenyx Pharmaceutical from In-Line to Outperform.
-
Cellectis SA (ADR) (NASDAQ: CLLS) shares gained
7.8 percent to $31.78.
-
The Rubicon Project Inc (NYSE: RUBI) shares surged
7.5 percent to $2.16 after falling 10.27 percent on Friday.
-
Uniqure NV (NASDAQ: QURE) gained 5.8 percent to
$19.02 after the company disclosed that it has received Orphan Medicinal Product Designation in Europe for AMT-130 in
Huntington's disease.
-
Wynn Resorts, Limited (NASDAQ: WYNN) shares rose
5 percent to $188.50 following strong Q4 results.
Losers
-
Sanmina Corp (NASDAQ: SANM) dropped 24.3 percent
to $26.85 after the company lowered its forecast for the first quarter and also issued a weak outlook for the second quarter.
-
Recon Technology, Ltd. (NASDAQ: RCON) declined 24
percent to $1.99. Recon Technology priced its 3.96 million share registered direct offering at $1.66 per share.
-
Idera Pharmaceuticals Inc (NASDAQ: IDRA) shares
fell 20.8 percent to $2.02. BioCryst Pharma and Idera Pharma announced plans to merge.
-
Forward Industries, Inc. (NASDAQ: FORD) dropped
17 percent to $2.46 after climbing 137.90 percent on Friday.
-
MagneGas Corporation (NASDAQ: MNGA) shares fell
11.2 percent to $3.18. MagneGas reported $1 million of industrial gas sales in the fourth quarter.
-
Future Fintech Group Inc (NASDAQ: FTFT) shares
slipped 11 percent to $3.37.
-
Ramaco Resources Inc (NASDAQ: METC) shares
slipped 10.4 percent to $8.07.
-
Sharing Economy International Inc (NASDAQ: SEII)
shares dropped 10.3 percent to $5.22.
-
US Gold Corp (NASDAQ: USAU) shares dropped 10
percent to $2.15.
-
ADT Inc (NYSE: ADT) shares fell 8.4 percent to
$11.35.
-
CTI BioPharma Corp (NASDAQ: CTIC) shares declined
7.2 percent to $3.25.
-
Shineco Inc (NASDAQ: TYHT) shares fell 6.3
percent to $2.23.
-
Inter Parfums, Inc. (NASDAQ: IPAR) slipped 4.1
percent to $45.85. Citigroup downgraded Inter Parfums from Buy to Neutral.
-
Palo Alto Networks Inc (NYSE: PANW) shares 3.6
percent to $151.61. Goldman Sachs downgraded Palo Alto from Buy to Neutral.
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.